Home > News > Advectus and Immune Announce Nano-Pharmaceutical Project Update
September 4th, 2003
Advectus and Immune Announce Nano-Pharmaceutical Project Update
Advectus Life Sciences Inc. announced today that it has acquired an option from Immune Network Ltd. which, if exercised, would give the Company an exclusive worldwide interest in a new nanotechnology-based formulation for the treatment of Alzheimer's disease based on compositions that penetrate the "blood-brain barrier" with existing drugs.
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Dartmouth Researchers Find Promising Results with Local Hyperthermia of Tumors March 4th, 2014